Sequoia Capital China and Morningside Ventures led a $100m Series B financing round in Virtue Diagnostics.

Sequoia Capital China, a VC firm focused on seed stage, mid stage, late stage, and growth investments in the fintech sector, and Morningside Ventures, a private equity firm, led a $100m Series B financing round in Virtue Diagnostics, an in-vitro diagnostics company. "Virtue's strategy is to introduce new technology platforms by cooperating with global technology companies, developing products and solutions specifically geared for the Chinese market and accelerating the time to market through our highly experienced team of R&D, registration and commercial professionals," Johnson Zhang, Virtue Diagnostics CEO.